#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
This article addresses a critical conflict of interest in medicinal cannabis practice: whether clinics should simultaneously prescribe and dispense cannabis products. Clinicians need clear ethical guidelines and regulatory standards on this issue to protect patients from potential overprescribing driven by financial incentives rather than clinical evidence. Understanding expert perspectives on this dual role helps practitioners navigate emerging cannabis medicine while maintaining the fiduciary duty patients expect in clinical care.
# Clinical Summary This article examines expert perspectives on the ethical and practical implications of clinic-based dispensary models, where healthcare facilities both prescribe and supply medicinal cannabis to patients. The conflict of interest concerns identified by the expert panel center on potential financial incentives that could bias prescribing practices, compromise clinical judgment, and undermine patient trust in the therapeutic recommendation. Vertical integration of prescribing and supply may also create barriers to price transparency and limit patient autonomy in choosing alternative products or pharmacies. The experts emphasize that separation of prescribing and dispensing functions, similar to established pharmaceutical practice standards, helps protect patients from inappropriate use and ensures recommendations are based solely on clinical evidence. Clinicians should be aware that regulatory frameworks governing cannabis supply models vary significantly across jurisdictions and may carry different ethical obligations depending on local law. Given the nascent evidence base for medicinal cannabis and patients’ vulnerability to inappropriate prescribing, clinicians should prioritize independent, evidence-based recommendations and counsel patients about sourcing options to maintain clinical integrity and therapeutic trust.
“The conflict of interest in clinic-supplied cannabis is real and clinically meaningful: when a physician profits from the product they’re recommending, it fundamentally compromises the objectivity that patients deserve, and it makes it nearly impossible to distinguish between genuine clinical benefit and financial incentive.”
💊 The question of whether clinics should both prescribe and dispense medicinal cannabis raises important tensions between patient access, conflict of interest management, and evidence-based practice. While vertical integration of prescribing and dispensing can theoretically improve medication adherence and continuity of care, it creates inherent financial incentives that may compromise clinical judgment and prioritize cannabis products over alternative evidence-based treatments. Clinicians should be aware that in jurisdictions where this model exists, financial relationships may influence prescribing patterns, particularly given the still-limited robust evidence for cannabis efficacy in many conditions. When counseling patients considering medicinal cannabis, providers should obtain an objective history of any financial relationships their clinic may have with dispensaries, seek out independent evidence reviews rather than relying solely on in-house recommendations, and document clear clinical rationales for cannabis use that align with current evidence and guidelines. Ultimately, the strongest clinical practice involves maintaining transparent separation between prescribing
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it: